NCT04705649View on ClinicalTrials.gov

Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 14, 2020

Primary Completion Date

June 22, 2023

Study Completion Date

June 22, 2023

Conditions
Endometrial Cancer
Interventions
OTHER

Treatment de-escalation

De-escalation from standard treatment based on molecular profile

Trial Locations (1)

V5Z 2E6

BC Cancer - Vancouver Centre, Vancouver

All Listed Sponsors
lead

British Columbia Cancer Agency

OTHER

NCT04705649 - Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer | Biotech Hunter | Biotech Hunter